Novanta Doubles Medical Consumables Revenue with Riverpoint Acquisition
Event summary
- Novanta completed the acquisition of Riverpoint Medical on July 27, 2026.
- Riverpoint is a leader in minimally invasive surgical consumables with revenue and cash flow growing at twice Novanta's rate.
- The deal doubles Novanta's recurring medical consumables revenue to approximately $300 million.
- Medical end-market exposure will increase to 60% of total revenue.
- Expected to be immediately accretive to organic growth, margins, and cash flows.
The big picture
Novanta's acquisition of Riverpoint Medical strengthens its position in the high-growth surgical consumables market, aligning with broader industry trends toward minimally invasive procedures. The deal underscores Novanta's strategic shift towards medical end-market dominance, positioning it to capitalize on increasing demand for advanced surgical technologies.
What we're watching
- Integration Execution
- How Novanta will integrate Riverpoint's operations and technologies to achieve the expected synergies.
- Market Expansion
- Whether Novanta can leverage Riverpoint's customer relationships to tap into a $2 billion incremental addressable market.
- Financial Performance
- The pace at which the acquisition contributes to adjusted earnings per share and overall financial metrics.
Related topics